Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 3Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Neurotoxicity Syndromes 1Lymphoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 17Magnetic Resonance Spectroscopy 16Radiotherapy 10Bevacizumab 7fluciclovine F-18 6Specimen Handling 6Topotecan 5Cyclophosphamide 5Biopsy 5fluorodopa F 18 4abemaciclib 4Vincristine 4Surgical Procedures, Operative 4Ketoconazole 4Irinotecan 4Fluorodeoxyglucose F18 4Ferrosoferric Oxide 4ribociclib 3gallium Ga 68 dotatate 3etoposide phosphate 3Radiation 3Pemetrexed 3Nivolumab 3Methotrexate 3Mesna 3Everolimus 3Etoposide 3Carboplatin 3posaconazole 2poly ICLC 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × motexafin gadolinium × CNS × Clear all
NCT00734773 2012-05-18

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Northwestern University

Phase EARLY_PHASE1 Withdrawn
CNSLymphoid

Lymphoma, Central Nervous System Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡